GlobeImmune, Inc. (GBIM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GlobeImmune, Inc. (GBIM) with AI Score 53/100 (Hold). GlobeImmune, Inc. is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases using its proprietary Tarmogen platform. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026GlobeImmune, Inc. (GBIM) Healthcare & Pipeline Overview
GlobeImmune, Inc. is a clinical-stage biopharmaceutical company leveraging its Tarmogen platform to develop immunotherapies for cancer and infectious diseases. With a focus on hard-to-treat diseases, the company is advancing a pipeline of product candidates through Phase 2 trials, while operating in a competitive biotechnology landscape.
Investment Thesis
GlobeImmune, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's Tarmogen platform offers a novel approach to immunotherapy, targeting a range of cancers and infectious diseases. Key value drivers include the successful advancement of its lead product candidates, particularly GS-4774 for hepatitis B and GI-6207 for medullary thyroid cancer, through clinical trials. Positive Phase 2 results and potential partnerships could significantly boost the company's valuation. However, the company's limited financial resources, reliance on collaborations, and the inherent risks associated with drug development pose significant challenges. With a negative P/E ratio and a market cap of $0.00B, the company's future hinges on clinical trial outcomes and securing additional funding.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 59.0% indicates potential profitability if products reach commercialization.
- Negative Profit Margin of -42.8% reflects ongoing R&D expenses and lack of product revenue.
- Beta of -200.46 suggests the stock price moves inversely to the market, but should be viewed with caution due to the company's financial state.
- Focus on Phase 2 clinical trials indicates progress in drug development, but also highlights the associated risks.
- Strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation provide potential for future funding and expertise.
Competitors & Peers
Strengths
- Proprietary Tarmogen platform technology.
- Pipeline of product candidates targeting multiple diseases.
- Strategic collaborations with Gilead and Celgene.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Dependence on collaborations for funding and expertise.
- High attrition rate in drug development.
- Lack of product revenue.
Catalysts
- Upcoming: Release of Phase 2 clinical trial results for GS-4774 in hepatitis B patients.
- Upcoming: Announcement of new strategic collaborations or partnerships.
- Upcoming: Presentation of data at scientific conferences related to cancer and infectious diseases.
- Ongoing: Advancement of preclinical programs targeting tuberculosis, HIV, and hepatitis D virus.
- Ongoing: Continued enrollment of patients in ongoing clinical trials.
Risks
- Potential: Failure to secure additional funding to support research and development.
- Potential: Negative clinical trial results for lead product candidates.
- Potential: Regulatory delays or rejection of product candidates.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Patent expiration and loss of intellectual property protection.
Growth Opportunities
- GS-4774 for Hepatitis B: The global hepatitis B therapeutics market is projected to reach billions of dollars by 2030. Successful Phase 2 trial results for GS-4774 could lead to partnerships or further development, capturing a share of this market. The timeline for potential commercialization depends on trial outcomes and regulatory approvals.
- GI-6207 for Medullary Thyroid Cancer: Medullary thyroid cancer represents a smaller, but still significant, market. Positive Phase 2 data for GI-6207 could position GlobeImmune as a key player in this niche area. The timeline for commercialization is contingent on clinical trial success and regulatory pathways.
- GI-4000 for Pancreatic, Lung, and Colorectal Cancers: The development of GI-4000 across multiple cancer types provides diversification and potential for broader market reach. Success in any of these indications could generate significant revenue. Clinical trials are ongoing, with commercialization timelines dependent on positive results.
- Preclinical Programs for Infectious Diseases: GlobeImmune's preclinical programs targeting tuberculosis, HIV, and hepatitis D virus represent long-term growth opportunities. These programs address significant unmet medical needs and could lead to breakthrough therapies. Development timelines are uncertain, but the potential market is substantial.
- Strategic Collaborations: Expanding strategic collaborations with pharmaceutical companies can provide GlobeImmune with funding, expertise, and access to larger markets. These partnerships can accelerate the development and commercialization of its product candidates. The timing and success of future collaborations are uncertain, but they represent a key growth driver.
Opportunities
- Positive clinical trial results for lead product candidates.
- Expansion of strategic collaborations.
- Out-licensing or partnering of product candidates.
- Securing additional funding through grants or equity offerings.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Patent expiration.
Competitive Advantages
- Proprietary Tarmogen platform technology provides a unique approach to immunotherapy.
- Pipeline of product candidates targeting a range of cancers and infectious diseases.
- Strategic collaborations with established pharmaceutical companies.
- Intellectual property protection for its Tarmogen platform and product candidates.
About GBIM
GlobeImmune, Inc., founded in 1995 and headquartered in Louisville, Colorado, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic products targeting cancer and infectious diseases. The company's core technology is its proprietary Tarmogen platform, which is designed to stimulate the body's immune system to fight disease. GlobeImmune's product pipeline includes several product candidates in various stages of clinical development. Key programs include GS-4774, currently in Phase 2 trials for the treatment of chronic hepatitis B virus infection, and GI-6207, also in Phase 2 trials for medullary thyroid cancer. Additionally, the company is developing GI-6301 for cancers expressing the brachyury protein, and GI-4000, which is in Phase 2b clinical trials for resected pancreas cancer and Phase 2 trials for non-small cell lung cancer and colorectal cancer. GlobeImmune also has preclinical programs targeting infectious diseases such as tuberculosis (GI-19000), HIV (GI-2010), and hepatitis D virus (GI-18000). The company collaborates strategically with Gilead Sciences, Inc. and Celgene Corporation to advance its research and development efforts. Formerly known as Ceres Pharmaceuticals, Inc., GlobeImmune adopted its current name in May 2001, marking a shift in its strategic focus towards immunotherapy.
What They Do
- Develop therapeutic products for cancer and infectious diseases.
- Utilize the proprietary Tarmogen platform to stimulate the immune system.
- Conduct Phase 2 clinical trials for GS-4774 to treat chronic hepatitis B virus infection.
- Develop GI-6207 for the treatment of medullary thyroid cancer.
- Develop GI-6301 for the treatment of cancers expressing the brachyury protein.
- Develop GI-4000 for the treatment of resected pancreas cancer, non-small cell lung cancer, and colorectal cancer.
- Conduct preclinical development of product candidates targeting tuberculosis, HIV, and hepatitis D virus.
Business Model
- Focus on developing and out-licensing or partnering its Tarmogen-based therapeutic products.
- Generate revenue through strategic collaborations with pharmaceutical companies.
- Seek funding through grants, equity offerings, and debt financing to support research and development.
- Potentially generate revenue from future product sales upon successful commercialization.
Industry Context
GlobeImmune operates in the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The market for cancer and infectious disease therapeutics is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. Key trends include the rise of immunotherapy and personalized medicine. GlobeImmune's Tarmogen platform positions it within the immunotherapy segment, competing with larger pharmaceutical companies and specialized biotech firms. Competitors are actively developing novel therapies, creating a dynamic and challenging landscape.
Key Customers
- Pharmaceutical companies seeking to license or acquire novel therapeutic products.
- Patients suffering from cancer and infectious diseases who may benefit from GlobeImmune's therapies.
- Healthcare providers who may prescribe GlobeImmune's products upon regulatory approval.
- Strategic partners such as Gilead Sciences, Inc. and Celgene Corporation.
Financials
Chart & Info
GlobeImmune, Inc. (GBIM) stock price: Price data unavailable
Latest News
No recent news available for GBIM.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GBIM.
Price Targets
Wall Street price target analysis for GBIM.
MoonshotScore
What does this score mean?
The MoonshotScore rates GBIM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Donald Bellgrau
CEO
Donald Bellgrau currently serves as the CEO of GlobeImmune, Inc. His responsibilities include managing the company's strategic direction and overseeing its research and development programs. With only two employees under his management, his role is highly hands-on and critical to the company's operations. Additional background information is not available.
Track Record: Due to limited information, Donald Bellgrau's specific achievements and strategic decisions at GlobeImmune, Inc. are not available. Evaluating his track record is challenging without detailed data on company milestones and financial performance under his leadership.
GBIM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GlobeImmune may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other market typically involves higher risks compared to exchanges like the NYSE or NASDAQ due to less stringent listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in GlobeImmune.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier has less regulatory oversight, increasing the risk of fraud or mismanagement.
- The company's ability to raise capital may be limited due to its OTC listing.
- Negative investor sentiment towards OTC-listed companies can impact stock price.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the management team.
- Assess the company's competitive landscape and market position.
- Evaluate the company's intellectual property and patent portfolio.
- Understand the company's business model and revenue streams.
- Consult with a financial advisor to assess the risks and potential rewards of investing in GlobeImmune.
- Check for any legal or regulatory issues involving the company.
- The company has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation.
- GlobeImmune has a proprietary Tarmogen platform technology.
- The company has product candidates in Phase 2 clinical trials.
What Investors Ask About GlobeImmune, Inc. (GBIM)
What does GlobeImmune, Inc. do?
GlobeImmune, Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The company's proprietary Tarmogen platform is designed to stimulate the body's immune system to fight disease. Its pipeline includes product candidates in various phases of clinical trials, targeting diseases such as hepatitis B, medullary thyroid cancer, and several other cancers. GlobeImmune aims to partner with or out-license its therapeutic products to pharmaceutical companies for further development and commercialization.
What do analysts say about GBIM stock?
As of 2026-03-16, there is no available analyst coverage or consensus on GlobeImmune, Inc. (GBIM) due to its OTC listing and limited market capitalization. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own thorough research and consider the risks associated with investing in a small, OTC-listed biotechnology company with limited financial resources and ongoing clinical trials.
What are the main risks for GBIM?
The main risks for GlobeImmune, Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's limited financial resources and dependence on collaborations for funding pose significant challenges. Competition from larger pharmaceutical companies with greater resources and established market presence is also a major risk. Additionally, patent expiration and loss of intellectual property protection could negatively impact the company's future prospects.
What are the key factors to evaluate for GBIM?
GlobeImmune, Inc. (GBIM) currently holds an AI score of 53/100, indicating moderate score. Key strength: Proprietary Tarmogen platform technology.. Primary risk to monitor: Potential: Failure to secure additional funding to support research and development.. This is not financial advice.
How frequently does GBIM data refresh on this page?
GBIM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GBIM's recent stock price performance?
Recent price movement in GlobeImmune, Inc. (GBIM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Tarmogen platform technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GBIM overvalued or undervalued right now?
Determining whether GlobeImmune, Inc. (GBIM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GBIM?
Before investing in GlobeImmune, Inc. (GBIM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete or outdated.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.